Primary results of ALESIA: Phase III, randomised open-label study of alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naïve ALK+ advanced non-small-cell lung cancer (NSCLC)

A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer

Annals of Oncology ◽

10.1093/annonc/mdz128 ◽

2019 ◽

Vol 30 (7) ◽

pp. 1127-1133 ◽

Cited By ~ 7

Author(s):

R.J. Kelly ◽

F.A. Shepherd ◽

A. Krivoshik ◽

F. Jie ◽

L. Horn

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Advanced Stage ◽

Small Cell Lung ◽

Open Label ◽

Open Label Study ◽

Preliminary Phase II results of a multicenter, open-label study of nazartinib (EGF816) in adult patients with treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC).

10.1200/jco.2018.36.15_suppl.9094 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 9094-9094 ◽

Cited By ~ 6

Author(s):

Dong-Wan Kim ◽

Daniel Shao-Weng Tan ◽

Santiago Ponce Aix ◽

Lecia V. Sequist ◽

Egbert F. Smit ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Treatment Naïve ◽

Egfr Mutant ◽

Preliminary Phase

A Phase 2 Randomized Open-Label Study of Ramucirumab (IMC 1121b; RAM) in Combination with Platinum-Based Chemotherapy in Patients (PTS) with Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC): Results From Non-Squamous (NSQ) PTS (NCT01160744)

Annals of Oncology ◽

10.1016/s0923-7534(20)33839-4 ◽

2012 ◽

Vol 23 ◽

pp. ix408 ◽

Cited By ~ 1

Author(s):

R. Doebele ◽

D. Spigel ◽

M. Tehfe ◽

S. Thomas ◽

M. Reck ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Platinum Based Chemotherapy

Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer

Cancer ◽

10.1002/cncr.29132 ◽

2014 ◽

Vol 121 (6) ◽

pp. 883-892 ◽

Cited By ~ 30

Author(s):

Robert C. Doebele ◽

David Spigel ◽

Mustapha Tehfe ◽

Sachdev Thomas ◽

Martin Reck ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Platinum Chemotherapy

Second-line erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): Results from a large, open-label study

10.1200/jco.2008.26.15_suppl.19002 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 19002-19002

Author(s):

L. Crinò ◽

M. Boyer ◽

W. E. Eberhardt ◽

Z. Balikó ◽

E. F. Smit

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Second Line ◽

Small Cell Lung ◽

Open Label ◽

Open Label Study ◽

A randomized open-label study of gefitinib versus docetaxel in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who have previously received platinum-based chemotherapy

10.1200/jco.2008.26.15_suppl.8025 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 8025-8025 ◽

Cited By ~ 8

Author(s):

D. Lee ◽

S. Kim ◽

K. Park ◽

J. Kim ◽

J. Lee ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Platinum Based Chemotherapy

168TiP KEYNOTE-A86: Phase III, randomized, open-label study of first-line subcutaneous (SC) vs intravenous (IV) pembrolizumab with platinum doublet chemotherapy in metastatic squamous or nonsquamous non-small cell lung cancer (NSCLC)

Annals of Oncology ◽

10.1016/j.annonc.2021.10.187 ◽

2021 ◽

Vol 32 ◽

pp. S1456

Author(s):

B. Halmos ◽

P. Cobb ◽

M.L. Johnson ◽

L. Jain ◽

S.J. Kim ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Doublet Chemotherapy ◽

Platinum Doublet

Randomized, open-label study of pemetrexed/carboplatin followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with advanced non-small cell lung cancer (NSCLC) of nonsquamous histology.

10.1200/jco.2010.28.15_suppl.tps290 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. TPS290-TPS290 ◽

Cited By ~ 1

Author(s):

R. Zinner ◽

S. Saxman ◽

G. Peng ◽

W. F. Ortuzar

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Open Label Study ◽

Updated results from TIGER-X, a phase I/II open label study of rociletinib in patients (pts) with advanced, recurrent T790M-positive non-small cell lung cancer (NSCLC).

10.1200/jco.2016.34.15_suppl.9045 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 9045-9045 ◽

Cited By ~ 3

Author(s):

Jonathan Wade Goldman ◽

Jean-Charles Soria ◽

Heather A. Wakelee ◽

D. Ross Camidge ◽

Shirish M. Gadgeel ◽

...

Keyword(s):

Lung Cancer ◽

Phase I ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Open Label Study ◽

A phase 2 randomized open-label study of ramucirumab (RAM) plus first-line platinum-based chemotherapy in patients (pts) with recurrent or advanced non-small cell lung cancer (NSCLC): Final results from squamous pts

Annals of Oncology ◽

10.1093/annonc/mdx091.039 ◽

2017 ◽

Vol 28 ◽

pp. ii42-ii43

Author(s):

S. Thomas ◽

R.C. Doebele ◽

D. Spigel ◽

M. Tehfe ◽

M. Reck ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Platinum Based Chemotherapy